โณ Fetching live dividend data...
Home โบ Calculator โบ SOLTF Dividend Calculator 2026
Nxera Pharma Co., Ltd. ยท OTC
Price: $8.43 ยท Annual div: None ยท Frequency: โ ยท Payout ratio: N/A ยท Ex-div: โ
SOLTF is not a dividend-focused stock
SOLTF pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Nxera Pharma Co., Ltd. (SOLTF) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise specializing in the development and global commercialization of pharmaceutical products. Operating across Japan, Switzerland, the United States, Bermuda, and the United Kingdom, the company provides a range of established treatments. Its current commercialized offerings include Ultibro/Breezhaler and Seebri/Breezhaler, both prescribed for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler, which are utilized in asthma management. Additionally, the portfolio features ORAVI, an innovative formulation for treating oropharyngeal candidiasis, and PIVLAZ, indicated for cerebral vasospasm. Looking to the future, Nxera Pharma maintains a robust research and development pipeline. This includes investigational compounds such as HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia disorders, Daridorexant for insomnia, and HTL0016878 for schizophrenia and other neuropsychiatric conditions. Other prospective therapies include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, PF-06954522 for metabolic diseases, NBI-1117569 for neurology diseases, and NBI-1117570 for central nervous system (CNS) disorders. The company is also advancing a GPR35 agonist for inflammatory bowel disease/GI disorders, currently in its preclinical phase, alongside various other early-stage discovery and preclinical research programs. To further its initiatives, Nxera Pharma has forged strategic alliances with prominent industry partners, including AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. The company was founded in 1990 and its corporate headquarters are located in Tokyo, Japan.
No. Nxera Pharma Co., Ltd. (SOLTF) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. SOLTF has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data ยท open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. ยท Privacy Policy
Ready to invest? Open SOLTF position with:
Real after-tax yield depends on where you live and how you hold SOLTF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| ๐บ๐ธ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| ๐บ๐ธ US Taxable (15%) โ | 15% | 0.00% | -2.80% | $0 / yr |
| ๐บ๐ธ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| ๐ฌ๐ง UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| ๐ฌ๐ง UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| ๐จ๐ฆ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| ๐จ๐ฆ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| ๐ฆ๐บ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| ๐ฆ๐บ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| ๐ฉ๐ช DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| ๐ซ๐ท FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr ยท ๐บ๐ธ US Taxable (15%) ยท static projection (no growth assumed).
SOLTF pays quarterly โ 4 times per year. Ex-div: โ.
How SOLTF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024โ2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SOLTF sourced from FMP /financial-growth endpoint โ real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores โ lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SOLTF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer โ
Nxera Pharma Co., Ltd. (SOLTF) is currently trading at $8.43, trading near its 52-week high. It does not currently pay a regular dividend.
Nxera Pharma Co., Ltd. (SOLTF) is a healthcare stock trading at $8.43. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only โ not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
โฑ๏ธ Takes 30 seconds ยท No signup ยท Free forever